Pioneering technologies that create novel antibody therapeutics to treat cancer and other serious diseases.
Research
Innovation
Discover how ÐǺ£ÆåÅÆ makes a positive impact for patients, communities, employees and the environment
Corporate and financial resources for ÐǺ£ÆåÅÆ investors, potential shareholders and analysts
Resources
Financials
Stock Information
Governance
Antibody Research and Development
Learn how ÐǺ£ÆåÅÆ leverages the power of antibody research and our immune system to translate discovery, preclinical and clinical insights into transformational antibody medicines
Our research and innovation teams comprise a strong antibody discovery engine connecting our antibody platform technologies with our target and disease biology knowledge. This synergy is the lifeblood of our R&D organization, where our creations enter clinical development.
We aim to invent, develop and commercialize antibody-based medicines which can be used in a modular fashion to create tailored therapeutics that transform the treatment of cancer and other serious diseases. Our translational research capabilities, which leverage biomarkers and companion diagnostics, are bringing us closer to delivering antibody therapeutics that deliver the right medicine to the right patient at the right dose.
Our antibody research and development teams integrate deep insights on patients, diseases and antibody modalities to:
- Expand our disease understanding using integrated omics, including deepening immunology and oncology expertise to discover novel targets and platforms
- Provide strong biological understanding of our therapies to help drive clinical development decision-making
- Enhance clinical development through data integration allowing for faster, real-time use of pharmacodynamic, mechanisms of action, and biomarker data to inform development plans
- Design, execute and interpret clinical trial pharmacodynamic/biomarker data for pivotal decisions on dose, patient outcomes and combinations
- Generate scientific insights using innovative computational approaches to integrate translational and clinical data
Our R&D Facilities
Innovation
ÐǺ£ÆåÅÆ Hosts Plenary and Life Science Fair on AI’s Role in the Future of Healthcare and Labs
14 October 2024
ÐǺ£ÆåÅÆ hosts an insightful event showcasing AI's role in digital transformation of healthcare, R&D, and labs of the future, connecting industry and healthcare experts, academia, and students.
Tools, techniques and technologies
In our product discovery, we connect our innovative antibody platform technologies with our robust target and disease biology knowledge to create novel and differentiating therapies.
Seamless integration of translational and quantitative approaches provides a strong scientific rationale and drives critical decisions from discovery to lifecycle management. It accelerates the development of medicines that deliver the right medicine, at the right dose, to the right patient, at the right time.
Data are transforming our understanding of diseases. This is especially true in cancer. We have invested in robust data science capabilities to enable rapid data-driven decision-making as we advance our products through all stages of research and development. Integration of disparate data sets from pre-clinical and clinical studies is a major guiding principle that is allowing us to extract novel insights regarding targets, investigational products, indications and patient biomarkers.
The development team works closely with healthcare professionals, regulatory bodies and patient advocacy groups to clinically develop antibody medicines. Operating at the forefront of clinical and medical innovation and patient care, the team uses medical, drug safety and pharmacovigilance insights, clinical trials, regulatory compliance, manufacturing and quality assurance to ensure the safety and efficacy of new treatments.
